Testing Market size is USD 2.24 Billion in 2025 and is expected to reach USD 6.66 Billion by 2035 due to the increasing adoption of NIPTAustin, March 10, 2026 (GLOBE NEWSWIRE) -- According to SNS ...

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...

DEAR DR. ROACH: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? -- M.N. ANSWER: When screening patients ...

When a tumor starts to grow in the body, small bits of its genetic material may break away and float off into the bloodstream. This so-called cell free DNA can be used to identify cancer at very early ...

A growing body of research seeks to validate ctDNA as a means of guiding MIBC treatment, particularly immunotherapy.

Pediatric ENT infections are prevalent and one of the most common reasons for antibiotic prescriptions. Turnaround times of conventional culturing assays are long leading to poor clinical management ...

Gene and cell therapy is moving fast – and in a clear direction. Programs are pushing toward more complex payloads, virus-free engineering, and manufacturing models that can scale from early research ...

Researchers at the University of Illinois Urbana-Champaign have built a computer simulation that tracks the entire life cycle ...

(MENAFN- GlobeNewsWire - Nasdaq) U.S. Cell-Free DNA (cfDNA) Testing Market size is USD 2.24 Billion in 2025 and is expected to reach USD 6.66 Billion by 2035 due to the increasing adoption of NIPT ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for ...